Jun 07,2023 TOP STORY

ASCO: AI-powered MOSAIC will build 3D atlas for cancer

The project – dubbed MOSAIC (Multi Omic Spatial Atlas in Cancer) – brings together a string of academic cancer research organisations, as well as artificial intelligence company Owkin, which specialises in machine learning models used to find new biomarkers and therapeutic targets from patient samples and spatial biology company NanoString. MOSAIC is starting life with $50 million in funding from Owkin, and will use a technique known as ‘spatial omics’, which combines gene sequencing with imaging technologies to analyse RNA and proteins not just for their presence or quantity, but also where they are physically located in cells and the microenvironment they inhabit. MOSAIC will focus initially on cancers with unmet medical needs, including non-small cell lung cancer, triple-negative breast cancer, diffuse large B cell lymphoma, ovarian cancer, glioblastoma, mesothelioma, and bladder cancer, said the partners.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023 TOP STORY

ASCO: Grail’s cancer blood test ‘promising’ in UK trial

Researchers in the UK say Grail’s blood test for more than 50 different types of cancer has shown promise in a trial involving thousands of people with suspected cancer symptoms. The team at Oxford University found that the Galleri multi-cancer early detection (MCED) test detected a cancer signal in 323 people presenting at a GP with suspected symptoms, 244 of whom subsequently had cancer diagnosed, giving a positive predictive accuracy of 75% in the 6,238-patient SYMPLIFY trial. The test was able to rule out cancer with around 98% predictive efficacy – meaning around 2% of patients with a negative result actually had cancer, and overall the test correctly revealed cancer 66% of the time. The SYMPLIFY trial is one of two large-scale community trials of the Galleri test being carried out in the UK, along with the NHS-Galleri study, which is evaluating it in up to 140,000 subjects and due to generate results sometime later this year.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Research featuring Elekta’s Kaiku Health platform to be presented at ASCO 2023

Personalized digital patient monitoring and support has become an important part of clinical research and routine care for growing number of patients globally. That’s why Kaiku Health are excited to be a part of clinical research published at ASCO 2023 in the two following sessions: Use and value of self-management recommendations in a real-world evidence study evaluating digital patient monitoring of patients receiving cancer care, and An interventional study of digital patient monitoring impact on health outcomes and healthcare resource utilization, and feasibility of combination with at-home treatment, in patients receiving systemic anticancer treatment in clinical practice.

CONFERENCES

#rwd

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Caris Life Sciences and ConcertAI Expand Partnership to Create First-in-Class, Prospectively Matched Clinico-Genomic Research Platform

Caris Life Sciences, the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, the leading oncology real-world evidence data and AI technology company, today announced an expanded translational sciences and clinical development solutions partnership. In the coming months, Caris and ConcertAI will create a prospectively generated, EHR-enabled and contemporaneously matched database of molecular, clinical and multi-modal data that will enable novel insights for precision medicine, therapeutic development and clinical trials management for academic and biopharma researchers.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Massive Bio Launches Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023 to Simplify and Expand Access to Oncology Clinical Trials

Massive Bio, a world-renowned provider of personalized oncology solutions, is set to showcase its GPT4 AI chatbots – AskFiona AI and DrArturo AI at ASCO 2023. AskFiona AI, an advanced AI chatbot, serves as a comprehensive guide through the intricacies of clinical trials. Adding depth to this patient-focused approach, DrArturo AI functions as an invaluable virtual oncology tool for providers including oncologists and hematologists. Offering detailed, personalized information about specific clinical trials, including treatment details and insurance acceptance, this AI tool aims to ensure patients, their families, and physicians are equipped with all necessary information to make informed decisions.

PRODUCT

#chatbot

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

Tempus Exhibits 20 Abstracts at the 2023 American Society of Clinical Oncology Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced the company will exhibit 20 abstracts at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from June 2-6, in Chicago, Illinois. This year, Tempus is presenting its latest research via two oral presentations, one poster discussion session, and several poster presentations.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide

Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC), a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools. PCC was established in 2022 with a shared vision of enabling access to comprehensive testing for all cancer patients globally, and is currently comprised of AstraZeneca, Bayer, Eli Lilly & Company, GSK, Johnson & Johnson/Janssen, Novartis, and Roche. The partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio’s Deep Learning Clinical Trial Matching System (DLCTMS). This will optimize the quality and efficiency of matching patients to trials across sponsor programs and improve patient access to targeted Next Generation Sequencing (NGS) testing and tailored interventions.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

New Data from Immunotherapy Quality of Life Study Accepted for Two Abstracts at 2023 ASCO

The Wave Health digital health platform, used to collect patient symptom and quality of life information in an innovative research study, comprises two abstracts accepted to the 2023 ASCO Annual Meeting. The study used TTI’s electronic patient reported outcomes (ePRO) platform to measure a variety of symptoms and aspects of health-related quality of life (HRQoL) in the “ImmunoWave” study, conducted at Fred Hutchinson Cancer Center. The study assessed for the presence of eleven symptoms and overall quality of life in a group of participants with prior exposure to ICI therapy or ongoing long-term ICI treatment. Participants in the study completed weekly symptom and HRQoL assessments using Wave Health. Participants reported frequent, persistent, and often severe symptoms, most notably fatigue, mental health symptoms and musculoskeletal symptoms. The study also identified which symptoms appeared to correlate most with diminished quality of life.

CLINICAL STUDY

#rwd

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

Jasper Health Joins Esteemed Founding Members of CancerX to Drive Cancer Moonshot Innovation Forward

Jasper Health is excited to announce its commitment to CancerX as a founding member alongside world-renowned organizations and institutions within the healthcare, digital health, oncology, pharmaceutical industries. Announced today at ASCO, CancerX – a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH) announced its full lineup of founding members, including Jasper Health.

View Analyst & Ambassador Comments
Go to original news
Jun 03,2023 TOP STORY

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, announced a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care. Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI’s active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services. Furthermore, this collaboration will expand the scope of cancer research through Massive Bio’s recent ChatGPT-powered chatbots for oncology research release during ASCO 2023.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#chatbot

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY